News & Views
One Nucleus Appoints Director
Oct 29 2010
One Nucleus, the not-for-profit membership company for international life science and healthcare companies, is delighted to announce the appointment of Dr Alan Palmer as a Director. Alan is co-founder and currently Chief Scientific Officer for MS Therapeutics Ltd and has 30 years’ experience in the biotechnology sector in roles spanning academia, research and industry.
Alan has close ties with the London life science and healthcare community and was a strong supporter of the London Biotechnology Network (LBN), now part of One Nucleus.
Commenting on his appointment Dr Palmer said: “I have worked with both Harriet (Fear) and Tony (Jones) for many years and am very excited about the merger of ERBI and LBN to form One Nucleus.
“These are challenging times and One Nucleus is extremely well placed to support the biotechnology sector. I am delighted to have been asked to join the Board and look forward to bringing my experience to the table, to support the team and One Nucleus members into the future.”
Harriet Fear, CEO of One Nucleus commented: “Alan is a great addition to the team. He has a deep understanding of the needs of One Nucleus members, and this coupled with his academic and pharma background makes him an ideal Director for One Nucleus.”
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 11 2024 Bangkok, Thailand